Business Description
Acumen Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00509G2093
Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.04 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.37 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -56.7 | |||||
| 3-Year EPS without NRI Growth Rate | -56.2 | |||||
| 3-Year FCF Growth Rate | -50.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -22.21 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.65 | |||||
| 9-Day RSI | 27.6 | |||||
| 14-Day RSI | 31.23 | |||||
| 6-1 Month Momentum % | 5.8 | |||||
| 12-1 Month Momentum % | -33.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.43 | |||||
| Quick Ratio | 10.43 | |||||
| Cash Ratio | 10.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.1 | |||||
| Shareholder Yield % | -33.6 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -32.14 | |||||
| ROA % | -28.1 | |||||
| ROIC % | -171.08 | |||||
| ROC (Joel Greenblatt) % | -20402.51 | |||||
| ROCE % | -28.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.5 | |||||
| Price-to-Tangible-Book | 0.49 | |||||
| EV-to-EBIT | 0.79 | |||||
| EV-to-Forward-EBIT | -0.06 | |||||
| EV-to-EBITDA | 0.79 | |||||
| EV-to-Forward-EBITDA | -0.06 | |||||
| EV-to-FCF | 0.97 | |||||
| Price-to-Net-Current-Asset-Value | 0.68 | |||||
| Price-to-Net-Cash | 0.71 | |||||
| Earnings Yield (Greenblatt) % | 126.58 | |||||
| FCF Yield % | -63.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acumen Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.38 | ||
| Beta | -0.27 | ||
| Volatility % | 95.36 | ||
| 14-Day RSI | 31.23 | ||
| 14-Day ATR ($) | 0.149034 | ||
| 20-Day SMA ($) | 2.0765 | ||
| 12-1 Month Momentum % | -33.61 | ||
| 52-Week Range ($) | 1.715 - 5.09 | ||
| Shares Outstanding (Mil) | 60.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acumen Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acumen Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acumen Pharmaceuticals Inc Frequently Asked Questions
What is Acumen Pharmaceuticals Inc(ABOS)'s stock price today?
The current price of ABOS is $1.79. The 52 week high of ABOS is $5.09 and 52 week low is $1.72.
When is next earnings date of Acumen Pharmaceuticals Inc(ABOS)?
The next earnings date of Acumen Pharmaceuticals Inc(ABOS) is 2025-03-26 Est..
Does Acumen Pharmaceuticals Inc(ABOS) pay dividends? If so, how much?
Acumen Pharmaceuticals Inc(ABOS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers